#Wellington #CAR T-Cell #New Zealand #BioOra #Wellington Zhaotai

BioOra and Wellington Zhaotai's Joint Venture for Global CAR T-Cell Therapy

In a significant development for cancer therapies, BioOra Limited, a New Zealand-based innovator in cell therapy, has entered into a binding Heads of Terms agreement with Wellington Zhaotai Therapies Limited (WZTL). This strategic partnership aims to enhance the global reach of their innovative third-generation CAR T-cell therapy, specifically the anti-CD19 CAR T-cell therapy known as WZTL-002. This therapy is designed to treat various conditions, including hematological malignancies and autoimmune disorders.

Advancing CAR T-Cell Therapy

The collaboration stands to provide BioOra with exclusive rights to develop and commercialize this therapy outside of China and India, amplifying its commercial potential in key markets such as the USA, Europe, and the UK. BioOra's existing partnership with the Malaghan Institute of Medical Research, which holds exclusive commercialization rights in New Zealand and Australia, serves as a foundational step in this global expansion.

The significance of CAR T-cell therapy cannot be understated; it has been heralded as one of the most important breakthroughs in oncology over the past decade. By employing a revolutionary automated manufacturing process utilizing the Cocoon® platform from the Octane Medical Group, BioOra promises a more consistent and cost-effective production of CAR T-cells, tackling the high costs and manufacturing challenges that have traditionally hampered the accessibility of these innovative therapies.

The Promise of Atla-Cel

BioOra has successfully combined Wellington Zhaotai's cutting-edge CAR-T technology with its own manufacturing and commercialization expertise to create Atla-cel, an autologous CAR T-cell entity. This product incorporates patented co-stimulatory domains aimed at enhancing efficacy while maintaining a favorable safety profile, with lower rates of neurotoxicity compared to its predecessors.

The clinical relevance of this third-generation design was highlighted in New Zealand's inaugural CAR T-cell clinical trial, ENABLE-1, which showcased BioOra's automated manufacturing capacity. This trial recorded impressive outcomes, with a complete response rate observed in 30 participants and a notably reduced incidence of serious toxicities compared to earlier CAR T-cell trials.

Currently, BioOra and the Malaghan Institute are validating the safety and efficacy of Atla-cel in a pivotal Phase 2 study, ENABLE-2, specifically targeting patients with relapsed or refractory large B-cell lymphoma. This study is crucial for securing registration in New Zealand and Australia and further emphasizes the partnership's commitment to addressing the needs of patients with serious blood cancers.

Empowering Global Access to Science

John Robson, the CEO of BioOra Limited, stated, "This agreement positions BioOra to expand Atla-cel into high-value global markets and marks an important commercial milestone for the company. The ultimate goal is to make CAR-T therapy affordable and accessible to patients worldwide who currently have limited treatment options. By merging Wellington Zhaotai's innovative approach with our advanced manufacturing skills, we can pave the way for broader patient access to CAR-T therapies."

Dr. Peter Crabtree, the Chairman of BioOra Limited, echoed this sentiment, emphasizing the global inequities in access to CAR T-cell therapy despite its groundbreaking efficacy. This partnership with Wellington Zhaotai not only signifies a commercial expansion for BioOra but also represents a solution to ensure patients suffering from blood cancers and related diseases receive effective treatments.

About the Companies

BioOra Limited is focused on developing next-generation cell therapies and is currently conducting Phase 2 trials for its lead product, Atla-cel. Founded in 2021 through a collaboration with the Malaghan Institute and the Bridgewest Group, its mission centers on delivering advanced therapies to patients beyond borders.

Wellington Zhaotai Therapies Limited was established in 2017 with a vision to create differentiated CAR T-cell therapies for the international market, built on a foundation of innovative research and development capability. The company seeks to convert groundbreaking cell therapy innovations into scalable commercial treatments, underpinned by a collaborative mission to address a variety of diseases.

In conclusion, the BioOra and Wellington Zhaotai partnership marks a significant step toward not only expanding the commercial landscape of CAR T-cell therapy but also ensuring equitable access to groundbreaking medical treatments that have the potential to change lives.